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Abstract 
Pancreatic tumors are rare in children and adolescents. Here, we report the case of a 15-year-
old boy who presented with a mixed acinar cell carcinoma/ductal adenocarcinoma with 
blastomatous components. He received multimodal treatment including various chemother-
apy regimens and multistep surgery including liver transplantation. Introduction of 
FOLFIRINOX after relapse repeatedly achieved a durable metabolic and clinical response with 
good quality of life. © 2013 S. Karger AG, Basel 
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Introduction 
Malignant tumors of the exocrine pancreas occur mainly in adults in their sixth or sev-
enth decade of life. They commonly present with late-stage disease, and have poor progno-
sis, even in cases with primary resectable disease. Most exocrine pancreatic tumors (~85%) 
are ductal adenocarcinomas. Less frequent histologies include intraductal papillary 
mucinous neoplasms with transition to an invasive carcinoma, serous cystadenocarcinomas 
or acinar cell carcinomas. In children, malignant pancreatic tumors are exceedingly rare, and 
only few reports are available [1–3]. Pediatric pancreatic tumors arise from embryonic 
precursor cells of ductal and acinar cells, and are termed pancreatoblastoma [3, 4]. Due to 
the stem cell origin of the tumor cells, pancreatoblastomas can subsequently differentiate to 
various histologic tumor cell types. 
Patients with pancreatic tumors often present with weight loss, jaundice, and varying 
abdominal symptoms due to the tumor mass effect [5].  
The treatment algorithm chosen usually depends on the type and stage of the respective 
tumor. An aggressive approach with complete tumor resection whenever possible seems to 
be the best primary option [2, 6, 7]. Patients with advanced disease may benefit from 
multimodality treatment [4, 8]. Primary systemic chemotherapy may be useful to reduce the 
tumor mass and allow subsequent secondary resection [9].  
Case Report 
A 15-year-old boy presented in November 2009 with a 3.2-cm tumor of the head of the 
pancreas and multiple diffuse liver metastases (fig. 1a, b). Liver and kidney function tests 
were within normal limits, serum alpha-fetoprotein (AFP) was elevated (400 U/ml). Biopsy 
of the liver mass revealed a malignant tumor with acinar cell differentiation, bringing up the 
differential diagnosis of acinar cell carcinoma, or a mixed tumor with acinar cell differentia-
tion including pancreatoblastoma. 
Chemotherapy was initiated with two cycles of cisplatin and doxorubicin (PLADO regi-
men), resulting in a partial response of the primary tumor and the liver metastases. Based on 
the good response, a Whipple duodenopancreatectomy and simultaneous wedge resection of 
the metastases of the left liver with ligation of the right portal vein were performed in March 
2010. Two additional cycles of the same chemotherapy were given postoperatively. 
The metastases of the right liver lobe were resected by hemihepatectomy of the right 
liver, any other lesions in the remnant liver were removed by wedge resection. In addition, 
focally infiltrated parts of the diaphragm were also resected. Altogether, this accounted for a 
surgical tumor reduction of about 90%. A central liver lesion could not be resected due to its 
vessel proximity. 
Surgical pathology confirmed a mixed histology with differentiation of both, acinar cell 
carcinoma and ductal adenocarcinoma. Some morphologic features of the primary liver 
biopsy also resembled an embryonic tumor, but the pathognomonic squamoid differentia-
tion of pancreatoblastoma was missing. One lymph node metastasis adjacent to the hepatic 
artery was found showing ductal differentiation. No neuroendocrine differentiation was 
detectable. Some tumor regression due to the preceding neoadjuvant chemotherapy was 
observed (fig. 2a–i). Immunostaining was focally positive for AFP in accordance with the 
initially elevated AFP serum levels. A diagnosis of a mixed acinar cell carcinoma/ductal 
adenocarcinoma was retained. 
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Tumor regrowth in the liver was observed on positron emission tomography/computed 
tomography (PET/CT) scan already 1 month after the second surgery. No tumor growth was 
seen in the remnant pancreas after Whipple resection. After subsequent second-line 
chemotherapy with two cycles of ifosphamide, carboplatin and etoposide (ICE regimen), a 
partial remission of the liver lesions was documented. 
A living donor liver transplantation (right hemiliver) from his brother was performed in 
November 2010. Due to a severe bile leak with abscess formation and finally hepatic artery 
thrombosis, the graft had to be replaced with a cadaveric liver graft after 10 days. After-
wards, the patient achieved complete recovery and was disease free. Immunosuppression 
with prednisone and tacrolimus was initially established. The former was subsequently 
tapered within 3 months, and tacrolimus was changed to everolimus. 
In April 2011, multiple new lung metastases were detected while no tumor relapse was 
seen in the abdomen. Therefore, in May 2011 a new chemotherapy treatment with 
oxaliplatin, irinotecan, leucovorin and 5-fluorouracil (FOLFIRINOX regimen) was started. 
The new treatment was tolerated well apart from neutropenia and thrombocytopenia up to 
grade 4, resulting in dose reductions of the applied compounds. After six biweekly cycles, 
PET/CT showed a complete metabolic and partial morphologic remission of all lung lesions 
(fig. 3a, b). 
Due to the excellent response to FOLFIRINOX, we decided to consolidate with tandem 
high-dose chemotherapy using carboplatin, etoposide and paclitaxel as conditioning regimen 
with subsequent autologous stem cell transplantation (ASCT). Hematopoietic progenitor 
cells were successfully mobilized with filgrastim, and high-dose chemotherapy was 
performed in November 2011 and February 2012. Due to transiently elevated liver enzymes 
after the first high-dose treatment, etoposide was omitted in the second treatment to reduce 
the toxicity for the transplanted liver.  
In August 2012, a progression of the pulmonary lesions was documented in a routine 
follow-up PET/CT. Treatment with FOLFIRINOX was once again initiated, resulting in a very 
good metabolic and morphologic remission after another six cycles until December 2012. 
Chemotherapy was continued for 3 additional months. While all lesions except one remained 
responsive to the treatment, the latter lesion was treated with stereotactic irradiation using 
3 × 12 = 36 Gy.  
As of today, the patient has a sustained metabolic remission of the known lung lesions 
and no new lesions developed with repeated use of FOLFIRINOX. He is currently in excellent 
general condition and has no limitations of his quality of life.  
Discussion 
No standard treatment for exocrine pancreatic tumors in pediatric patients has been 
defined due to the rarity of this disease. Accordingly, treatment decisions were based on 
guidelines and recommendations of the Children’s Cancer and Leukaemia Group (CCLG) on 
the management of rare tumors like hepatoblastoma and pancreatoblastoma, as well as on 
treatment algorithms used in adult patients with pancreatic cancer. Surgical resection of 
large tumor masses seems to be the best first-line therapy in resectable tumors, even when 
microscopically incomplete. Recently, a successful treatment with high-dose chemotherapy 
and ASCT of a young patient with a pancreatoblastoma has been reported after incomplete 
primary resection [10]. The few reported cases of high-dose chemotherapy and ASCT in 
young patients suggesting a benefit from aggressive multimodality treatment prompted us 
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to perform tandem transplantation in our patient after observing good tolerability and an 
excellent response to initial standard dose chemotherapy [11–13].  
The tumor tissue was heterogeneous showing different lines of differentiation. Predom-
inantly, the primary tumor in the pancreas and most of the liver metastases showed a mixed 
acinar and ductal cell differentiation, while some liver lesions were predominantly of acinar 
cell type. In addition, some morphologic features of the liver lesions resembled pancreato-
blastoma, although a typical squamoid differentiation of the tumor cells was lacking. One can 
speculate that this heterogeneous tumor may well have been a pancreatoblastoma with 
differentiation along various cell types, which could finally not be diagnosed due to the 
regressive changes of the tumor morphology after neoadjuvant chemotherapy. Recently, the 
phenotype of a pancreatic carcinoma showing combined acinar cell and ductal differentia-
tion was described and discussed as a possible distinctive tumor entity with an aggressive 
clinical course [14]. Irrespective of the diagnostic label, the tumor was regarded as 
malignant with mixed differentiation including acinar cell carcinoma, ductal adenocarcino-
ma, and blastomatous components, each associated with different biological behavior, 
respectively. 
The course of our patient allows the following conclusions. Firstly, despite the fact that 
advanced and metastatic pancreatic tumors are generally considered to have a dismal 
prognosis, an aggressive multimodal treatment strategy in young and fit patients may result 
in improvement of quality of life and survival. In addition, treatment with high-dose 
chemotherapy and subsequent ASCT was possible even after orthotopic liver transplanta-
tion. Our patient is now in excellent condition without showing any clinical symptoms 
related to the tumor almost 4 years after the initial diagnosis. He is going to school and is not 
compromized in his daily living. 
Secondly, the repeated use of FOLFIRINOX may be highly active also in pancreatic tu-
mors other than ductal adenocarcinoma. In our patient, the best response to systemic 
chemotherapy was achieved with FOLFIRINOX, although only given as third-line chemother-
apy and despite the pretreatment with various other compounds. Convincing data have been 
reported for the FOLFIRINOX treatment of adult patients with ductal adenocarcinoma of the 
pancreas in the first-line setting, but no data exist in pretreated patients with other rare 
tumor entities [15]. Our patient showed an excellent response even after repeated use of this 
treatment combination. 
In conclusion, FOLFIRINOX has proven to be a highly active chemotherapy regimen in 
this heavily pretreated patient and may be a very good alternative to older and more toxic 
regimens for the treatment of pediatric patients presenting with rare pancreatic tumors. 
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Fig. 1. a PET/CT showing the primary tumor in the pancreatic head, 3 cm in diameter with weak 
fluorodeoxyglucose avidity (standard uptake value 3.8; arrowheads). In addition, a large liver metastasis 
can be seen in the left liver lobe (arrow). b Multiple large liver metastases are shown predominantly in the 
right liver lobe. 
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Fig. 2. Histopathological findings of pancreas and liver resection specimens. a Overview of the pancreas; 
resection after chemotherapy. The tumor shows both acinar cell differentiation (left) and ductal 
differentiation (right), as well as regressive changes (scale bar = 2 mm). b High-power view of the former 
picture (scale bar = 1 mm). c Perineural infiltration by the acinar cell tumor component. The arrow points 
to the peripheral nerve (scale bar = 0.8 mm). d Mostly regressive perihilar lymph node metastasis 
(arrows); resection after chemotherapy (scale bar = 10 mm). e High-power view of the former picture 
showing few ductal differentiated vital tumor deposits in a regressive background (scale bar = 0.5 mm). f 
Overview of a liver metastasis with cystic regressive areas with hemorrhage; resection after chemothera-
py (scale bar = 10 mm). g Overview of another liver metastasis (arrows); resection after chemotherapy 
(scale bar = 10 mm). h High-power view of the former picture shows a tumor with blastomatous features 
(scale bar = 1 mm). i MIB-1 staining reveals a high-proliferation rate of the blastomatous tumor 
component (scale bar = 0.9 mm). 
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Fig. 3. a PET/CT showing multiple new fluorodeoxyglucose avid lung metastases. No relapse could be 
seen in the abdomen. b Complete metabolic response of the lesions after treatment with FOLFIRINOX.  
 
